目的 探讨苦参碱对肺癌A549细胞增殖、侵袭和血管生成抑制作用以及其作用机制。方法 不同浓度苦参碱组加入到A549人肺癌细胞株中，利用ELISA法研究了苦参碱对EGFR-TPK的抑制作用，利用MTT法测定苦参碱对A549细胞的抑制作用，Transwell法检测苦参碱对肺癌A549细胞侵袭的抑制作用，酶标仪法检测苦参碱对细胞凋亡蛋白caspase 3活性的影响，Western blotting法检测苦参碱存在下A549中VEGF、HIF-1α的表达。结果 苦参碱对EGFR-TPK半数抑制率为11.26±1.02 μmol/L，对肺癌A549细胞生长IC₅₀为30.45±3.02 μmol/L，都具有良好的抑制能力，但对于MRC-5细胞表现了较低的毒性；苦参碱与对照组相比能够诱导肿瘤细胞穿过人工基底膜的数量减少，差异有显著性（P<0.05）；与对照组比较，苦参碱能显著提高A549中凋亡蛋白caspase 3活性（P<0.05）；苦参碱能够下调HIF-1α和VEGF的表达。结论 苦参碱可降低EGFR-TPK活性和HIF-1α、VEGF的表达，激活caspase 3活性，对肺癌肿瘤A549细细胞的侵袭、增殖和血管生成产生抑制作用。

Objective To study the inhibition of matrine on proliferation, invasion, and angiogenesis of A549 lung cancer tumor cells, and explore its mechanisms. Methods Matrine with various concentration was added to human lung cancer A549 cell line. The inhibitory effect of matrine against EGFR-TPK was investigated by ELISA method, the inhibitory rate of matrine against A549 was determined by MTT method, and inhibitory effect of matrine on invasion of lung cancer A549 cells was studied by Transwell assay. The effect of matrine on the activity of apoptotic protein caspase 3 was detected by enzyme labeling method, and finally the effect of matrine on expression of angiogenesis related protein VEGF and HIF-1α of A549 tumor cells were discussed. Results Matrine has good restrain ability on EGFR-TPK and A549 cells with IC₅₀ of (11.26±1.02) and (30.45±3.02) μmol/L, but showed low toxicity for MRC-5 cells. Compared with the control group, matrine could induce the number of tumor cells to pass through the artificial basement membrane, with significant difference between two groups (P < 0.05). Compared with the control group, matrine could significantly increase caspase 3 activity of A549 (P < 0.05), and the expression of angiogenesis related protein VEGF and HIF-1α of A549 tumor cells were down-regulated. Conclusion Matrine can reduce the activity of EGFR-TPK and the expression of HIF-1 and VEGF, activate the activity of caspase 3, and inhibit the invasion, proliferation and angiogenesis of lung cancer A549 cells.

河南省医学科技攻关计划项目（201203068）